Donidalorsen for COVID-19: real-time analysis

Download Image

Post

c19early.org

Donidalorsen for COVID-19

1 study with 103 patients

Serious outcome risk

Donidalorsen

Control

COVID-19 Donidalorsen studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−151%

Mortality (1)−151%

RCTs (1)−151%

Late (1)−151%

00.511.5+

← Donidalorsen
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Aug 3 2024	Zampieri et al., Journal of Critical Care, doi:10.1016/j.jcrc.2024.154892	Antisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial
Aug 3 2024	151% higher mortality (p=0.08), 81% higher ventilation (p=0.08), and 35% higher progression (p=0.03). RCT 111 hospitalized COVID-19 patients in Brazil showing no clinical benefit with antisense therapy to block the kallikrein-kinin pathway using ISIS 721744 (donidalorsen). Treatment was associated with a significantly higher SOFA score at..